Omnicare — Q3 2014 Earnings Presentation
16 slides from Omnicare's earnings presentation, Oct 24, 2014
Slide 1: Omnicare
Omnicare
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain of mace lovey it i the following re fe ‘d-lookir i i vate ities Litigation Reform Act of 1995. These forward-| Hooking statements include, but are not tte to, all statements ir ue intent, belief or Current regarding Such and involve k and orleaan risks, uncertainti
Slide 3: Table of Contents
_ Appendix. _ Gross Profit & Adjusted Operating Income. Table of Contents Mhird-Quarter 2014 HIGHIQHUS ssi isssssscsescenesaeavsavasevessevesteccvenveeteterestsereee 4 Operating Metrics — Script Data Adjusted Net Income & Cash EPS....... Adjusted Operating Income by Segment Cash Flows — Cash Deploym
Slide 4: Third-Quarter 2014 Highlights
Third-Quarter 2014 Highlights") + Revenue of $1,608M; 6.1% year-over-year increase Adjusted operating income of $153M; 5.8% year-over-year increase — 23 bps adjusted operating margin expansion from previous quarter, largest sequential increase since 1013 Adjusted cash earnings per diluted share of $
Slide 5: Operating Metrics - Script Data
Operating Metrics Script Data") Sequential Prior Year Increase / (In thousands, except %s) 3Q.2014 22014 (Decrease) _3Q2013 (Decrease) Long-Term Care Group Scripts: Generic scripts dispensed 20,506 20,671 (0.8%) 20,469 0.2% Branded scripts dispensed 3,892 3,956 (1.6%) 4,194 (7.2%) Over-the-counter s
Slide 6: Gross Profit & Adjusted Operating Income
Gross Profit & Adjusted Operating Income )2) Sequential Prior Year Increase / Increase / In millions, except per share data and %s 3Q2014 22014 (Decrease) _3Q2013 (Decrease) Net sales $1,608.1 $1,610.6 (0.2%) “$ 1,515.2 6.1% Cost of sales 1,256.6 1,256.4 0.0% 1,163.2 8.0% Gross profit $ 351.5 $ 354.
Slide 7: Adjusted Net Income & Cash EPS
Adjusted Net Income & Cash EPS()@) t " Increase / In mitions, except per share data and %s 3.2014 202014 Decrease) 302013 (Decrease) i $ 1526 $ 149.1 2.3% 144.3 5.8% "Adjusted interest expense, net of investment income (22.6) (23.4) (2.2%) (23.9) 6.4%) Adjusted income before income taxes 130.0 126.0
Slide 8: Adjusted Operating Income by Segment
Adjusted Operating Income by Segment (1) Sequential increase / 302014 _ 20.2014 Decieass) 3013 Cosas) In millions, except %s Long-Term Care Group sales $1,183.4 $ 1,190.4 (1%) $ 1,158.0 2% 2 158. 160.0 (1%) ____ 158.5 0% Rate 13.41% 18.44% 3bps 13.68% —— -27 bps In whole numbers Per script data: Net
Slide 9: Cash Flows
Gash Flows (1) Sequential Prior Year Increase / Increase / — Inmilions, exc 3Q2014 202014 (Decrease) _3Q2013 (Decrease) Net income / (Loss| 648 $ 22.0 194.5% $ (66.3) (197.7%) (Income) / Loss from discontinued operations $ 32 $ 393 (91.9%) $ (8.0) (206.7%) Adjustments to reconcile net income to net
Slide 10: Cash Deployment
Cash Deployment Sequential Prior Year Increase / Increase / In millions, except % 3Q2014 202014 (Decrease) _3Q2013_ (Decrease) Net cash flows from of spare activities of continuing operations (reported) $ (36.0) $218.6 (116.5%) $ 1888 (119.1%) Capital expenditures 19.8 21.9 (9.6%) 27.0 (26.7%) Acqui
Slide 11: Full-Year 2014 Guidance
Full-Year 2014 Guidance ] Original Previous Guidance“) Guidance®) | * Net sales $6.3B to $6.4B $6.3B to $6.4B - Adjusted cash earnings per diluted share from $3.64 to $3.72 $3.64 to $3.72 continuing operations) + Cash flow from continuing operations ®) $475M to $550M $500M to $550M Current Guidance)
Slide 12: Appendix
RNY ly, “yg; Omnicare Appendix
Slide 13: Capital Structure
Capital Structure Major Debt Maturity Schedule” ‘$1,800 As of 9/30/10 As of 9/30/14 $1,500 ~ $1,200 2035 ™ | | M1 \ | 2010 2015 2020 2025, 2030 2040 2045, Continue to focus on leveraging our afta balance sheet to spread out and lower b ig costs 2083, 2035: hal * Omnicare 2018 204 13
Slide 14: Working Capital Management
Working Capital Management Five Quarter Trend() 75 40 70 35 65 60 30 55 25 50 20 45 6 429 | 447 40 39.2 10 =i 38 5 30 3013 4013 1014 2014 3014 —e-Days of Inventory On Hand (DOH) — —e=Days Sales Outstanding (DSO) Improvements in DSO have benefitted operating cash flows; allowing opportunistic working
Slide 15: Selected Branded Drug Patent Expirations
Micardis IR Micardis HCT Epivir-HBV Tabs 2Q14 - Launched Actonel (150MG) Evista 3Q14 — Launched Diovan IR Evista Exforge IR il Gray font indicates launch has akeady ocoure, 2014 Baraclude Celebrex Extorge HCT Intuniv Oxycontin (Limited Launch) Patanase 2015 Ability ‘Actonel (35MG) Renvela Welchol Zy
Slide 16: Omnicare
Omnicare